Galantide

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(NCC(N2[C@@H](CCC2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)CC3=CC=CC=C3)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)=O)=O)NC(CNC([C@H](C)NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@@H](NC(CN)=O)CC5=CNC6=CC=CC=C56)=O)=O)=O)=O)=O)=O)=O

[1]Langel U, et al. Design of chimeric peptide ligands to galanin receptors and substance P receptors. Int J Pept Protein Res. 1992;39 (6) :516-522.|[2]Lindskog S, et al. The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. Eur J Pharmacol. 1992;210 (2) :183-188.|[3]Mulvaney JM, et al. Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons. Eur J Pharmacol. 1995;287 (1) :97-100.